Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 402Colorectal Neoplasms 317Rectal Neoplasms 235Stomach Neoplasms 209Pancreatic Neoplasms 137Neoplasm Metastasis 123Colonic Neoplasms 94Neoplasms 86Triple Negative Breast Neoplasms 64Esophageal Neoplasms 57Biliary Tract Neoplasms 39Nasopharyngeal Carcinoma 37Cholangiocarcinoma 31Adenocarcinoma 31Carcinoma, Hepatocellular 30Gallbladder Neoplasms 29Carcinoma, Non-Small-Cell Lung 21Bile Duct Neoplasms 21Locally Advanced Rectal Cancer 20Adenocarcinoma Of Esophagus 20Squamous Cell Carcinoma of Head and Neck 19Brain Neoplasms 19Gastrointestinal Neoplasms 18Parkinson Disease 4, Autosomal Dominant Lewy Body 17Liver Neoplasms 17Head and Neck Neoplasms 17Esophageal Squamous Cell Carcinoma 17Colorectal Cancer Metastatic 15Ovarian Neoplasms 14Breast Neoplasms, Male 14

Interventions

Injections 3Fluorouracil 2Cisplatin 2toripalimab 1spartalizumab 1pembrolizumab 1SHR-1701 1Paclitaxel 1Oxaliplatin 1Irinotecan 1Gemcitabine 1Drug Therapy 1Docetaxel 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Malignant Tumors × Capecitabine × Clear all
NCT05235542 2022-08-11

A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors

Akeso

Phase 1/2 Unknown
130 enrolled

Advanced Malignant Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡